Exact Sciences Showcases New Data Highlighting Cologuard's Success in Boosting Cancer Screening Rates

Author: Benzinga Newsdesk | October 27, 2025 06:12am

Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced new data being presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting, taking place October 24–29, 2025, at the Phoenix Convention Center in Phoenix, Arizona. The company's research showcases leadership in advancing colorectal cancer (CRC) screening through high-quality science, real-world evidence, and innovations that improve screening adherence and access across diverse patient populations. ACG abstracts are available on their website.

"Exact Sciences' research at ACG 2025 underscores our leadership in advancing evidence-based, patient-centered screening solutions that improve adherence and outcomes," said Paul Limburg, MD, MPH, AGAF, Chief Medical Officer for Screening, Exact Sciences. "The data continue to highlight how our comprehensive support, coupled with robust science, make Cologuard and Cologuard Plus best-in-class tools for early colorectal cancer detection."

The studies presented at ACG 2025 align with Exact Sciences' mission to increase screening participation in underserved and vulnerable populations, including those served by Federally Qualified Health Centers, safety-net facilities, Rural Health Clinics, and the Indian Health Service. The findings reinforce the importance of multifaceted programs, outreach and patient support in overcoming persistent barriers to screening and follow-up care.

The abstracts at ACG are as follows:

(RWE.88) Reaching the Unscreened: Adherence Outcomes from an mt-sDNA CRC Screening Care Gap Program

• Summary: Among 2,095 Medicare Advantage enrollees without a point-of-care mt-sDNA test order, 53.4% of prior mt-sDNA users and 38.8% of those with previous use of another stool-based test completed screening through a care gap closure program. Prior mt-sDNA users were 74% more likely to complete screening than those with prior FIT use. Digital communications significantly improved engagement, with participants 129% more likely to complete testing after receiving digital outreach. CRC screening care gap programs demonstrate the potential to improve CRC screening rates by reaching individuals who may otherwise not interact with the health care system.
• Session: Monday, October 27, 2025, 10:30 AM – 4:00 PM

(REC.10.3) FIT-Based Colorectal Cancer Screening Completion Rates (Initial Test and Follow-up Colonoscopy) by Health Facility Type: A Systematic Review and Meta-Analysis

• Summary: Across 47 studies evaluating 405 intervention strategies, overall adherence to FIT screening was 35.7%, increasing modestly to 39.4% among those receiving an intervention, compared with 26.1% without intervention. Adherence to follow-up colonoscopy after a positive FIT was 46.6%, underscoring substantial gaps in completion rates.
• Session: Tuesday, October 28, 2025, 10:30 AM – 4:00 PM

(MS.44) One-Time Colorectal Cancer Screening with Next-Generation mt-sDNA vs FIT: Clinical and Economic Impact Using a Comprehensive Cost-Calculator Economic Model

• Summary: A hypothetical cohort of 1 million average-risk individuals was modeled to simulate the estimated outcomes from one round of next-generation mt-sDNA versus FIT screening. Next-generation mt-sDNA screened more than twice as many patients as FIT (713,000 vs 318,000) and achieved 5.7x more HEDIS® quality targets. It detected 5.5x more advanced precancerous lesions (21,701 vs 3,328), 3.7x more colorectal cancer cases (2,090 vs 440), and prevented 5.5x more cancers (1,736 vs 266). It also cut treatment costs by 3% and total costs by 2% compared to FIT ($1,388M vs $1,423M).
• Session: Monday October 27, 2025, 10:30 AM – 4:00 PM

Posted In: EXAS